XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -7.94%1.78B | 35.22%539.8M | -1.42%340M | -12.23%445.5M | -33.25%456.2M | 37.30%1.94B | 6.97%399.2M | 167.36%344.9M | 55.04%507.6M | 17.87%683.4M |
Net income from continuing operations | 25.25%844.7M | 27.31%244.3M | -1.42%97M | 122.68%103.1M | 18.50%400.3M | -14.83%674.4M | -20.44%191.9M | 54.96%98.4M | -17.03%46.3M | -21.68%337.8M |
Operating gains losses | 0.00%2.9M | -47.06%1.8M | -150.00%-500K | ---- | ---- | 102.75%2.9M | --3.4M | 33.33%-200K | ---- | ---- |
Depreciation and amortization | 14.86%1.04B | 8.08%278.1M | 27.79%269.5M | 8.75%253.5M | 17.01%242.1M | 10.65%908.2M | 19.01%257.3M | 3.79%210.9M | 11.69%233.1M | 7.37%206.9M |
Deferred tax | 25.28%168M | 84.06%58.9M | 163.74%24M | 34.29%23.5M | -18.41%61.6M | -14.53%134.1M | -17.10%32M | -48.00%9.1M | 28.68%17.5M | -13.42%75.5M |
Other non cash items | -110.59%-125.3M | -19.14%-55.4M | -713.04%-37.4M | -607.50%-28.3M | 4.55%-4.2M | -258.43%-59.5M | -4.97%-46.5M | -133.82%-4.6M | -165.57%-4M | -155.00%-4.4M |
Change In working capital | -180.99%-195.6M | 56.49%-31.5M | -140.26%-12.6M | -57.16%92.1M | -460.36%-243.6M | 191.79%241.5M | 29.98%-72.4M | 118.58%31.3M | 397.69%215M | 296.51%67.6M |
-Change in receivables | -155.13%-101.5M | ---- | ---- | ---- | ---- | 185.11%184.1M | ---- | ---- | ---- | ---- |
-Change in inventory | -56.39%102M | ---- | ---- | ---- | ---- | 190.34%233.9M | ---- | ---- | ---- | ---- |
-Change in prepaid assets | -306.81%-75.9M | ---- | ---- | ---- | ---- | 474.49%36.7M | ---- | ---- | ---- | ---- |
-Change in payables and accrued expense | 129.49%81M | ---- | ---- | ---- | ---- | -215.23%-274.7M | ---- | ---- | ---- | ---- |
-Change in other current liabilities | 489.55%26.1M | 276.19%23.7M | -12.50%-900K | 224.74%12.1M | -252.00%-8.8M | 73.73%-6.7M | 141.45%6.3M | 98.05%-800K | -124.13%-9.7M | 73.68%-2.5M |
-Change in other working capital | -433.28%-227.3M | 76.50%-60.8M | -136.45%-11.7M | -64.40%80M | -434.95%-234.8M | 657.78%68.2M | -263.32%-258.7M | 125.18%32.1M | 7,390.00%224.7M | 381.53%70.1M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -7.94%1.78B | 35.22%539.8M | -1.42%340M | -12.23%445.5M | -33.25%456.2M | 37.30%1.94B | 6.97%399.2M | 167.36%344.9M | 55.04%507.6M | 17.87%683.4M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 10.04%-3.21B | 25.26%-798.5M | 27.24%-820.5M | -34.46%-871M | 0.66%-723M | -38.96%-3.57B | -20.37%-1.07B | -54.14%-1.13B | -11.56%-647.8M | -96.49%-727.8M |
Capital expenditure reported | 1.20%-2.61B | 0.03%-760M | 12.30%-634.7M | -4.13%-629.8M | -5.82%-589.5M | -20.09%-2.65B | -11.78%-760.2M | -19.42%-723.7M | -29.54%-604.8M | -23.77%-557.1M |
Net PPE purchase and sale | ---29M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Net investment purchase and sale | 2,700.00%75.4M | ---- | ---- | ---- | ---- | -231.82%-2.9M | ---- | ---- | ---- | ---- |
Net other investing changes | 30.07%-645.4M | 72.18%-84.9M | 54.01%-185.8M | -460.93%-241.2M | 21.79%-133.5M | -149.91%-922.9M | -45.61%-305.2M | -221.66%-404M | 62.21%-43M | -314.18%-170.7M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 10.04%-3.21B | 25.26%-798.5M | 27.24%-820.5M | -34.46%-871M | 0.66%-723M | -38.96%-3.57B | -20.37%-1.07B | -54.14%-1.13B | -11.56%-647.8M | -96.49%-727.8M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -116.94%-651M | -89.50%298.5M | -27.91%503.4M | 130.00%420.9M | -1,697.44%-1.87B | 236.65%3.84B | 456.37%2.84B | 20.04%698.3M | -17.72%183M | 167.45%117.3M |
Net issuance payments of debt | -108.76%-240.1M | -58.24%342.3M | -83.73%101.2M | -51.61%505.5M | -565.04%-1.19B | 84.34%2.74B | 70.68%819.6M | -11.32%622M | 195.78%1.04B | 640.59%255.7M |
Net common stock issuance | 4,648.84%612.6M | 3,072.73%104.7M | 15,121.21%502.3M | -12.12%2.9M | -10.00%2.7M | -91.64%12.9M | -97.73%3.3M | 3.13%3.3M | 6.45%3.3M | 7.14%3M |
Net preferred stock issuance | -24.99%-500.1M | --0 | --0 | --0 | ---500.1M | ---400.1M | --0 | --0 | ---400.1M | --0 |
Cash dividends paid | -6.98%-489.2M | -11.21%-124M | -6.72%-119.1M | 2.85%-119.4M | -13.84%-126.7M | -4.74%-457.3M | 2.96%-111.5M | -7.83%-111.6M | -7.06%-122.9M | -7.64%-111.3M |
Net other financing activities | -101.76%-34.2M | -101.15%-24.5M | -89.71%19M | 109.33%31.9M | -101.33%-60.6M | 3,143.35%1.94B | 355,266.67%2.13B | 1,051.55%184.6M | -1,690.58%-342M | -15.77%-30.1M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -116.94%-651M | -89.50%298.5M | -27.91%503.4M | 130.00%420.9M | -1,697.44%-1.87B | 236.65%3.84B | 456.37%2.84B | 20.04%698.3M | -17.72%183M | 167.45%117.3M |
Net cash flow | ||||||||||
Beginning cash position | 2,925.33%2.28B | 48.97%158.8M | -28.89%135.9M | -5.26%140.5M | 2,925.33%2.28B | -20.55%75.4M | 35.62%106.6M | 92.06%191.1M | 13.73%148.3M | -20.55%75.4M |
Current changes in cash | -194.41%-2.08B | -98.17%39.8M | 127.10%22.9M | -110.75%-4.6M | -3,036.35%-2.14B | 11,411.28%2.21B | 68,053.13%2.17B | -304.31%-84.5M | 238.51%42.8M | 105.35%72.9M |
End cash Position | -91.29%198.6M | -91.29%198.6M | 48.97%158.8M | -28.89%135.9M | -5.26%140.5M | 2,925.33%2.28B | 2,925.33%2.28B | 35.62%106.6M | 92.06%191.1M | 13.73%148.3M |
Free cash flow | -21.22%-861.5M | 30.97%-249.2M | 22.20%-294.7M | -89.61%-184.3M | -205.54%-133.3M | 10.46%-710.7M | -17.63%-361M | 20.59%-378.8M | 30.32%-97.2M | -2.62%126.3M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |